---
title: "阿斯利康：在 DESTINY - Breast05 三期試驗中，與恩美曲妥珠單抗相比，優赫得使接受新輔助治療的高危 HER2 陽性早期乳腺癌患者的疾病復發或死亡風險降低了 53%。"
description: "阿斯利康：在 DESTINY - Breast05 三期試驗中，與恩美曲妥珠單抗相比，優赫得使接受新輔助治療的高危 HER2 陽性早期乳腺癌患者的疾病復發或死亡風險降低了 53%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261731605.md"
published_at: "2025-10-18T14:39:23.000Z"
---

# 阿斯利康：在 DESTINY - Breast05 三期試驗中，與恩美曲妥珠單抗相比，優赫得使接受新輔助治療的高危 HER2 陽性早期乳腺癌患者的疾病復發或死亡風險降低了 53%。

阿斯利康：在 DESTINY - Breast05 三期試驗中，與恩美曲妥珠單抗相比，優赫得使接受新輔助治療的高危 HER2 陽性早期乳腺癌患者的疾病復發或死亡風險降低了 53%。

### Related Stocks

- [AZN.US - 阿斯利康](https://longbridge.com/zh-HK/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients | AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients | [Link](https://longbridge.com/zh-HK/news/276444179.md) |
| AstraZeneca PLC $AZN Shares Sold by Ontario Teachers Pension Plan Board | Ontario Teachers Pension Plan Board reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 41% in Q3, now holding 817,880  | [Link](https://longbridge.com/zh-HK/news/276339476.md) |
| Maine CDC reports 4 additional cases of measles have been confirmed in Maine | Maine CDC reports 4 additional cases of measles have been confirmed in Maine | [Link](https://longbridge.com/zh-HK/news/276164223.md) |
| Daiichi Sankyo and AstraZeneca get EU validation for Enhertu use | Daiichi Sankyo and AstraZeneca have received validation from the European Medicines Agency for their application to exte | [Link](https://longbridge.com/zh-HK/news/276408087.md) |
| 08:46 ETCenter for Asbestos Related Disease, Inc. (CARD) Invites Community Members to Attend an Open House and Ribbon Cutting Celebration | The Center for Asbestos Related Disease, Inc. (CARD) is hosting an Open House and Ribbon Cutting celebration on February | [Link](https://longbridge.com/zh-HK/news/276235741.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。